| scholarly article | Q13442814 |
| P50 | author | Mark A. Lemmon | Q24076870 |
| P2093 | author name string | Sung Hee Choi | |
| Monica Red Brewer | |||
| Graham Carpenter | |||
| Ambra Pozzi | |||
| Katarina Moravcevic | |||
| Diego Alvarado | |||
| P2860 | cites work | An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor | Q24293598 |
| Mechanism of activation and inhibition of the HER4/ErbB4 kinase | Q24310089 | ||
| Crystallography & NMR System: A New Software Suite for Macromolecular Structure Determination | Q26778405 | ||
| Processing of X-ray diffraction data collected in oscillation mode | Q26778468 | ||
| Structural basis for autoinhibition of the Ephb2 receptor tyrosine kinase by the unphosphorylated juxtamembrane region | Q27635000 | ||
| Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor | Q27639528 | ||
| Structure of a c-kit product complex reveals the basis for kinase transactivation | Q27641501 | ||
| The structural basis for autoinhibition of FLT3 by the juxtamembrane domain | Q27643077 | ||
| Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity | Q27644014 | ||
| 6-Ethynylthieno[3,2-d]- and 6-ethynylthieno[2,3-d]pyrimidin-4-anilines as tunable covalent modifiers of ErbB kinases | Q27649889 | ||
| Cell signaling by receptor tyrosine kinases | Q27860474 | ||
| Use of TLS parameters to model anisotropic displacements in macromolecular refinement | Q27860499 | ||
| Coot: model-building tools for molecular graphics | Q27860505 | ||
| Structure validation by Calpha geometry: phi,psi and Cbeta deviation | Q27860657 | ||
| Likelihood-enhanced fast rotation functions | Q27860684 | ||
| The conformational plasticity of protein kinases | Q27860946 | ||
| Shape complementarity at protein/protein interfaces | Q27860963 | ||
| The CCP4 suite: programs for protein crystallography | Q27861090 | ||
| Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain | Q27865182 | ||
| A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells | Q28282744 | ||
| Analysis of deletions of the carboxyl terminus of the epidermal growth factor receptor reveals self-phosphorylation at tyrosine 992 and enhanced in vivo tyrosine phosphorylation of cell substrates | Q28624927 | ||
| Phosphorylation of tyrosine residues in the kinase domain and juxtamembrane region regulates the biological and catalytic activities of Eph receptors | Q28647596 | ||
| Epidermal growth factor receptor mutations in lung cancer | Q29615474 | ||
| EGFR antagonists in cancer treatment | Q29616740 | ||
| The HER family and cancer: emerging molecular mechanisms and therapeutic targets | Q34558080 | ||
| Erlotinib in lung cancer - molecular and clinical predictors of outcome | Q34559274 | ||
| ErbB receptors: new insights on mechanisms and biology | Q34579265 | ||
| Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity | Q35684026 | ||
| Juxtamembrane autoinhibition in receptor tyrosine kinases. | Q35790329 | ||
| Epidermal growth factor receptor juxtamembrane region regulates allosteric tyrosine kinase activation | Q36288511 | ||
| An electrostatic engine model for autoinhibition and activation of the epidermal growth factor receptor (EGFR/ErbB) family | Q36493654 | ||
| A negative feedback loop attenuates EGF-induced morphological changes | Q36530153 | ||
| 'Classical' but not 'other' mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer | Q36610717 | ||
| ERK-dependent threonine phosphorylation of EGF receptor modulates receptor downregulation and signaling | Q37036809 | ||
| Ligand-induced ErbB receptor dimerization | Q37154122 | ||
| Epidermal growth factor (EGF) receptor T669 peptide kinase from 3T3-L1 cells is an EGF-stimulated "MAP" kinase | Q37448443 | ||
| Mutational removal of the Thr669 and Ser671 phosphorylation sites alters substrate specificity and ligand-induced internalization of the epidermal growth factor receptor | Q38339773 | ||
| Autoinhibition of the kit receptor tyrosine kinase by the cytosolic juxtamembrane region. | Q39745856 | ||
| EGF-independent activation of cell-surface EGF receptors harboring mutations found in gefitinib-sensitive lung cancer | Q40235641 | ||
| The epidermal growth factor receptor juxtamembrane domain has multiple basolateral plasma membrane localization determinants, including a dominant signal with a polyproline core | Q40713310 | ||
| Nuclear localization of EGF receptor and its potential new role as a transcription factor | Q40782527 | ||
| EGF receptor residues leu(679), leu(680) mediate selective sorting of ligand-receptor complexes in early endosomal compartments | Q40861554 | ||
| A leucine-based determinant in the epidermal growth factor receptor juxtamembrane domain is required for the efficient transport of ligand-receptor complexes to lysosomes | Q40978824 | ||
| The human epidermal growth factor receptor contains a juxtamembrane calmodulin-binding site. | Q42832751 | ||
| A basic peptide within the juxtamembrane region is required for EGF receptor dimerization | Q45149243 | ||
| Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer | Q46493689 | ||
| Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression | Q46735221 | ||
| Characterization of a novel tripartite nuclear localization sequence in the EGFR family. | Q50698452 | ||
| Protein kinase C phosphorylation of the EGF receptor at a threonine residue close to the cytoplasmic face of the plasma membrane | Q59070337 | ||
| Isolation and characterization of two growth factor-stimulated protein kinases that phosphorylate the epidermal growth factor receptor at threonine 669 | Q68248821 | ||
| Mutation of Di-leucine residues in the juxtamembrane region alters EGF receptor expression | Q71807852 | ||
| Threonine phosphorylation diverts internalized epidermal growth factor receptors from a degradative pathway to the recycling endosome | Q73804934 | ||
| Increased plasma MMP9 in integrin alpha1-null mice enhances lung metastasis of colon carcinoma cells | Q81499755 | ||
| P433 | issue | 6 | |
| P921 | main subject | cell biology | Q7141 |
| P304 | page(s) | 641-51 | |
| P577 | publication date | 2009-06-26 | |
| P1433 | published in | Molecular Cell | Q3319468 |
| P1476 | title | The Juxtamembrane Region of the EGF Receptor Functions as an Activation Domain | |
| P478 | volume | 34 |
| Q50293429 | A New Method to Study Heterodimerization of Membrane Proteins and Its Application to Fibroblast Growth Factor Receptors |
| Q38683823 | A brief perspective of drug resistance toward EGFR inhibitors: the crystal structures of EGFRs and their variants |
| Q38753496 | A cell-free method for expressing and reconstituting membrane proteins enables functional characterization of the plant receptor-like protein kinase FERONIA. |
| Q33723892 | A highly efficient peptide substrate for EGFR activates the kinase by inducing aggregation |
| Q64278999 | A low-molecular-weight compound exerts anticancer activity against breast and lung cancers by disrupting EGFR/Eps8 complex formation |
| Q28485213 | A potential peptide therapeutic derived from the juxtamembrane domain of the epidermal growth factor receptor |
| Q54278801 | A premature termination of human epidermal growth factor receptor transcription in Escherichia coli. |
| Q35674768 | A structural perspective on the regulation of the epidermal growth factor receptor |
| Q37816649 | A view into the blind spot: solution NMR provides new insights into signal transduction across the lipid bilayer. |
| Q36579570 | Access to the nucleus and functional association with c-Myc is required for the full oncogenic potential of ΔEGFR/EGFRvIII |
| Q93198405 | Actionable Activating Oncogenic ERBB2/HER2 Transmembrane and Juxtamembrane Domain Mutations |
| Q39346046 | Activation of the EGF Receptor by Ligand Binding and Oncogenic Mutations: The "Rotation Model". |
| Q26849316 | Adaptive resistance to targeted therapies in cancer |
| Q34395251 | Allosteric communication across the native and mutated KIT receptor tyrosine kinase |
| Q35058437 | Analysis of Somatic Mutations in Cancer: Molecular Mechanisms of Activation in the ErbB Family of Receptor Tyrosine Kinases |
| Q38780920 | Analysis of a single-codon E746 deletion in exon 19 of the epidermal growth factor receptor |
| Q35917462 | Analysis of the Role of the C-Terminal Tail in the Regulation of the Epidermal Growth Factor Receptor |
| Q36923502 | Architecture and membrane interactions of the EGF receptor |
| Q34025360 | Asp-960/Glu-961 controls the movement of the C-terminal tail of the epidermal growth factor receptor to regulate asymmetric dimer formation |
| Q42284635 | Bipartite tetracysteine display reveals allosteric control of ligand-specific EGFR activation |
| Q37642081 | Calmodulin-mediated regulation of the epidermal growth factor receptor. |
| Q98726033 | Canonical ErbB-2 isoform and ErbB-2 variant c located in the nucleus drive triple negative breast cancer growth |
| Q35026889 | Carboxyl-group footprinting maps the dimerization interface and phosphorylation-induced conformational changes of a membrane-associated tyrosine kinase. |
| Q35219426 | Catalytic control in the EGF receptor and its connection to general kinase regulatory mechanisms. |
| Q24598357 | Cell signaling by receptor tyrosine kinases |
| Q40565356 | Cell-free synthesis of functional human epidermal growth factor receptor: Investigation of ligand-independent dimerization in Sf21 microsomal membranes using non-canonical amino acids |
| Q37890208 | Changing pathology with changing drugs: tumors of the gastrointestinal tract |
| Q28834399 | Characterization of membrane protein interactions in plasma membrane derived vesicles with quantitative imaging Förster resonance energy transfer |
| Q33778237 | Co-conserved features associated with cis regulation of ErbB tyrosine kinases |
| Q27323236 | Coarse-grained molecular simulation of epidermal growth factor receptor protein tyrosine kinase multi-site self-phosphorylation |
| Q40259833 | Comparative proteomic analysis of compartmentalised Ras signalling |
| Q34625617 | Complex relationship between ligand binding and dimerization in the epidermal growth factor receptor |
| Q31036423 | Computational modeling of allosteric communication reveals organizing principles of mutation-induced signaling in ABL and EGFR kinases |
| Q33760518 | Conformational changes in receptor tyrosine kinase signaling: an ErbB garden of delights |
| Q24313122 | Conformational coupling across the plasma membrane in activation of the EGF receptor |
| Q54644212 | Conformational regulation of the EGFR kinase core by the juxtamembrane and C‐terminal tail: A molecular dynamics study |
| Q41188895 | Consequences of replacing EGFR juxtamembrane domain with an unstructured sequence |
| Q34149071 | Convergence between Wnt-β-catenin and EGFR signaling in cancer |
| Q28115187 | Crucial roles of RSK in cell motility by catalysing serine phosphorylation of EphA2 |
| Q24303022 | Cytohesins are cytoplasmic ErbB receptor activators |
| Q90252710 | Deep mutational analysis reveals functional trade-offs in the sequences of EGFR autophosphorylation sites |
| Q27027644 | Design principles underpinning the regulatory diversity of protein kinases |
| Q39493031 | Differential action of small molecule HER kinase inhibitors on receptor heterodimerization: therapeutic implications |
| Q100512363 | Direct stimulation of ERBB2 highlights a novel cytostatic signaling pathway driven by the receptor Thr701 phosphorylation |
| Q33996985 | EGF receptor exposed to oxidative stress acquires abnormal phosphorylation and aberrant activated conformation that impairs canonical dimerization |
| Q50288594 | EGF-induced dimerization of ligand-responsive EGFR mutants |
| Q47680913 | EGFR Ligands Differentially Stabilize Receptor Dimers to Specify Signaling Kinetics |
| Q34406334 | EGFR-mutated lung cancer: a paradigm of molecular oncology |
| Q43080915 | EGFR: tale of the C-terminal tail |
| Q35221485 | Effect of phosphorylation on EGFR dimer stability probed by single-molecule dynamics and FRET/FLIM. |
| Q27305848 | Enhanced dimerization drives ligand-independent activity of mutant epidermal growth factor receptor in lung cancer |
| Q28084565 | ErbB polymorphisms: insights and implications for response to targeted cancer therapeutics |
| Q35755192 | ErbB2 Is Necessary for ErbB4 Ligands to Stimulate Oncogenic Activities in Models of Human Breast Cancer |
| Q24621754 | ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation |
| Q93370017 | ErbB4 point mutation in CU3 inbred rats affects gonadotropin-releasing-hormone neuronal function via compromised neuregulin-stimulated prostaglandin E2 release from astrocytes |
| Q52767309 | Expanding the search for significant EGFR mutations in NSCLC outside of the tyrosine kinase domain with next-generation sequencing. |
| Q36974435 | Exploring higher-order EGFR oligomerisation and phosphorylation--a combined experimental and theoretical approach |
| Q41729710 | Feedback control of ErbB2 via ERK-mediated phosphorylation of a conserved threonine in the juxtamembrane domain. |
| Q54246031 | Finding the missing links in EGFR. |
| Q37212883 | Free Energy Landscape of Lipid Interactions with Regulatory Binding Sites on the Transmembrane Domain of the EGF Receptor |
| Q36611657 | Function and mode of action of cytohesins in the epidermal growth factor pathway in colorectal cancer cells |
| Q33747967 | Her4 and Her2/neu tyrosine kinase domains dimerize and activate in a reconstituted in vitro system |
| Q34133387 | Human epidermal growth factor receptor (HER1) aligned on the plasma membrane adopts key features of Drosophila EGFR asymmetry |
| Q54578263 | In silico screening of epidermal growth factor receptor (EGFR) in the tyrosine kinase domain through a medicinal plant compound database. |
| Q60049457 | In the literature: December 2018 |
| Q41826289 | Influence of macrocyclization on allosteric, juxtamembrane-derived, stapled peptide inhibitors of the epidermal growth factor receptor (EGFR). |
| Q27314725 | Inhibition of Receptor Dimerization as a Novel Negative Feedback Mechanism of EGFR Signaling |
| Q42858861 | Insider Influence on ErbB Activity |
| Q41984481 | Interactions of the EGFR juxtamembrane domain with PIP2-containing lipid bilayers: Insights from multiscale molecular dynamics simulations |
| Q39131097 | Inverse correlation between Thr-669 and constitutive tyrosine phosphorylation in the asymmetric epidermal growth factor receptor dimer conformation |
| Q85857386 | Investigating Molecular Mechanisms of Activation and Mutation of the HER2 Receptor Tyrosine Kinase through Computational Modeling and Simulation |
| Q34133392 | Investigating extracellular in situ EGFR structure and conformational changes using FRET microscopy. |
| Q35121287 | Kinase activator-receiver preference in ErbB heterodimers is determined by intracellular regions and is not coupled to extracellular asymmetry |
| Q34352792 | Kinase-mediated quasi-dimers of EGFR |
| Q49887882 | Kinase-targeted cancer therapies: progress, challenges and future directions |
| Q35733874 | Ligand regulation of a constitutively dimeric EGF receptor |
| Q40323830 | Ligand-independent Tie2 dimers mediate kinase activity stimulated by high dose angiopoietin-1. |
| Q33526877 | Lineage-specific co-evolution of the Egf receptor/ligand signaling system |
| Q93366506 | Long-range molecular dynamics show that inactive forms of Protein Kinase A are more dynamic than active forms |
| Q39355055 | MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors |
| Q35657617 | Mechanics of EGF receptor/ErbB2 kinase activation revealed by luciferase fragment complementation imaging |
| Q54979674 | Mechanism of Allosteric Coupling into and through the Plasma Membrane by EGFR. |
| Q41831994 | Mechanism of FGF receptor dimerization and activation |
| Q36368323 | Mechanisms for kinase-mediated dimerization of the epidermal growth factor receptor |
| Q33883884 | Mechanisms of activation of receptor tyrosine kinases: monomers or dimers |
| Q39056242 | Mechanisms of epidermal growth factor receptor signaling as characterized by patterned ligand activation and mutational analysis |
| Q49888000 | Mechanisms of receptor tyrosine kinase activation in cancer |
| Q36887721 | Mechanisms of resistance to EGFR targeted therapies |
| Q39603355 | Mechanistic insights into the activation of oncogenic forms of EGF receptor |
| Q36852720 | Mig6 is a sensor of EGF receptor inactivation that directly activates c-Abl to induce apoptosis during epithelial homeostasis |
| Q28548302 | Mitogen-Inducible Gene-6 Mediates Feedback Inhibition from Mutated BRAF towards the Epidermal Growth Factor Receptor and Thereby Limits Malignant Transformation |
| Q36993693 | Molecular basis for multimerization in the activation of the epidermal growth factor receptor |
| Q92539355 | Molecular designing, virtual screening and docking study of novel curcumin analogue as mutation (S769L and K846R) selective inhibitor for EGFR |
| Q42822469 | Molecular dynamics analysis of conserved hydrophobic and hydrophilic bond-interaction networks in ErbB family kinases |
| Q37602884 | Molecular modeling of ErbB4/HER4 kinase in the context of the HER4 signaling network helps rationalize the effects of clinically identified HER4 somatic mutations on the cell phenotype |
| Q37349031 | Mutations in the polybasic juxtamembrane sequence of both plasma membrane- and endoplasmic reticulum-localized epidermal growth factor receptors confer ligand-independent cell transformation |
| Q42174975 | Mutual cross-talk between fibronectin integrins and the EGF receptor: Molecular basis and biological significance |
| Q35378448 | N-Glycosylation as determinant of epidermal growth factor receptor conformation in membranes |
| Q38740481 | Overcoming resistance to HER2 inhibitors through state-specific kinase binding |
| Q28483701 | Overexpression of CARMA3 in non-small-cell lung cancer is linked for tumor progression |
| Q36765270 | Pairwise detection of site-specific receptor phosphorylations using single-molecule blotting |
| Q38573858 | Pharmacokinetics, pharmacodynamics and clinical efficacy of pertuzumab in breast cancer therapy |
| Q35762279 | Phosphatidylinositol-4,5-bisphosphate regulates epidermal growth factor receptor activation |
| Q33905397 | Phosphorylation-dependent differential regulation of plant growth, cell death, and innate immunity by the regulatory receptor-like kinase BAK1. |
| Q37917164 | Physical-chemical principles underlying RTK activation, and their implications for human disease |
| Q39089524 | Piecing it together: Unraveling the elusive structure-function relationship in single-pass membrane receptors |
| Q34297973 | Plakophilin-2 promotes activation of epidermal growth factor receptor |
| Q35585497 | Potentiation of epidermal growth factor-mediated oncogenic transformation by sialidase NEU3 leading to Src activation |
| Q38280501 | Putting together structures of epidermal growth factor receptors |
| Q42141122 | Quantitative analysis reveals how EGFR activation and downregulation are coupled in normal but not in cancer cells |
| Q40289950 | RET Functions as a Dual-Specificity Kinase that Requires Allosteric Inputs from Juxtamembrane Elements |
| Q34773458 | Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer |
| Q89956925 | Receptor tyrosine kinase activation: From the ligand perspective |
| Q37694979 | Receptor tyrosine kinase transmembrane domains: Function, dimer structure and dimerization energetics |
| Q38193038 | Receptor tyrosine kinases: legacy of the first two decades |
| Q52708724 | Regulation of Kinase Activity in the Caenorhabditis elegans EGF Receptor, LET-23. |
| Q35021986 | Regulation of human EGF receptor by lipids |
| Q35597077 | Regulation of the catalytic activity of the EGF receptor. |
| Q39430410 | Regulation of the ligand-dependent activation of the epidermal growth factor receptor by calmodulin. |
| Q34532338 | Reorienting the Fab domains of trastuzumab results in potent HER2 activators |
| Q62648881 | Review: Precision medicine and driver mutations: Computational methods, functional assays and conformational principles for interpreting cancer drivers |
| Q39038580 | S-Fms signalobody enhances myeloid cell growth and migration |
| Q38796060 | Signals and Receptors |
| Q33981031 | Simultaneous visualization of the extracellular and cytoplasmic domains of the epidermal growth factor receptor |
| Q27342307 | Single Particle Tracking Reveals that EGFR Signaling Activity Is Amplified in Clathrin-Coated Pits |
| Q91721637 | Single-molecule functional anatomy of endogenous HER2-HER3 heterodimers |
| Q39731307 | Spatial control of EGF receptor activation by reversible dimerization on living cells |
| Q50288595 | Spontaneous dimerization of ligand-responsive EGFR mutants |
| Q27664092 | Structural Basis for Negative Cooperativity in Growth Factor Binding to an EGF Receptor |
| Q36446161 | Structural Basis for the Non-catalytic Functions of Protein Kinases. |
| Q35820920 | Structural analysis of the EGFR/HER3 heterodimer reveals the molecular basis for activating HER3 mutations |
| Q27646596 | Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3 |
| Q33810641 | Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell lung cancer |
| Q37599025 | Structural characterization of nonactive site, TrkA-selective kinase inhibitors. |
| Q41844310 | Structural templates for modeling homodimers |
| Q92934599 | Structure and Dynamics of the EGF Receptor as Revealed by Experiments and Simulations and Its Relevance to Non-Small Cell Lung Cancer |
| Q30368961 | Structure-based network analysis of activation mechanisms in the ErbB family of receptor tyrosine kinases: the regulatory spine residues are global mediators of structural stability and allosteric interactions. |
| Q26853162 | Structure-function relationships of ErbB RTKs in the plasma membrane of living cells |
| Q38987589 | Structure-functional prediction and analysis of cancer mutation effects in protein kinases. |
| Q38719332 | Studying the Conformation of a Receptor Tyrosine Kinase in Solution by Inhibitor-Based Spin Labeling |
| Q64993166 | Suppression of Wnt/β-catenin signaling by EGF receptor is required for hair follicle development. |
| Q33769117 | Synthesis and biochemical characterization of EGF receptor in a water-soluble membrane model system |
| Q38267209 | Targeting RAS-mutant cancers: is ERK the key? |
| Q36077604 | Temporal resolution of autophosphorylation for normal and oncogenic forms of EGFR and differential effects of gefitinib. |
| Q46659031 | The Axl kinase domain in complex with a macrocyclic inhibitor offers first structural insights into an active TAM receptor kinase |
| Q38201344 | The EGFR family: not so prototypical receptor tyrosine kinases |
| Q54498075 | The ERBB network: at last, cancer therapy meets systems biology. |
| Q58600328 | The architecture of EGFR's basal complexes reveals autoinhibition mechanisms in dimers and oligomers |
| Q31038185 | The energy landscape analysis of cancer mutations in protein kinases |
| Q47572757 | The free energy landscape in translational science: how can somatic mutations result in constitutive oncogenic activation? |
| Q51741088 | The intracellular juxtamembrane domain of discoidin domain receptor 2 (DDR2) is essential for receptor activation and DDR2-mediated cancer progression. |
| Q41206091 | The juxtamembrane regions of human receptor tyrosine kinases exhibit conserved interaction sites with anionic lipids |
| Q35639911 | The membrane-proximal intracellular domain of the epidermal growth factor receptor underlies negative cooperativity in ligand binding |
| Q37977179 | The regulatory role of the juxtamembrane region in the activity of the epidermal growth factor receptor |
| Q34267140 | Trafficking of epidermal growth factor receptor ligands in polarized epithelial cells |
| Q37704902 | Transmembrane helix-helix interactions involved in ErbB receptor signaling. |
| Q42064359 | Tyrosine phosphorylation of mig6 reduces its inhibition of the epidermal growth factor receptor. |
| Q35247477 | Understanding the molecular basis of EGFR kinase domain/MIG-6 peptide recognition complex using computational analyses |
| Q36406773 | Unliganded EphA3 dimerization promoted by the SAM domain |
| Q38998168 | Up-regulation of plakophilin-2 is correlated with the progression of glioma |
| Q35551725 | β3 integrin-EGF receptor cross-talk activates p190RhoGAP in mouse mammary gland epithelial cells. |
Search more.